Conference Coverage
about 2 months ago
Jamie Michael, MD, discusses MRI and genomics in active surveillanceabout 2 months ago
Matthew Truesdale, MD, on IsoPSA performance with and without mpMRILatest News
Aug 31, 2026 | Opinion
Prof Declan Murphy discusses PROTEUS pathologic response findings in prostate cancer
Zachary Feuer, MD, on building a rapid access program for prostate cancer diagnostic evaluation
Aug 31, 2026
Timothy McClure, MD, on 2-year PRESERVE trial results for focal IRE
Aug 31, 2026
Mary Dunn, MSN, RN, NP-C, OCN, on the role of APPs in genetic testing
Aug 29, 2026
FDA greenlights phase 1 trial of ADI-212 in mCRPC
Aug 28, 2026
Advertisement
Shorts
0:41
Erectile dysfunction and cardiovascular health: An opportunity for urologists
13 hours ago
by
Mark T. Edney, MD
0:32
Why urology and REI collaboration needs to start earlier
4 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:04
Nerve-sparing prostatectomy: Surgical gestures linked to erectile function recovery
5 days ago
by
Andrew J. Hung, MD
0:48
Nocturia in older adults: Understanding its clinical significance
5 days ago
by
Kari A.O. Tikkinen, MD, PhD
0:35
The case for permanent Medicare payment reform in urology
7 days ago
by
Celeste Kirschner, CAE, MHSA
0:49
The UroOnc Minute: Emphasizing cribriform and IDC reporting in prostate cancer
8 days ago
by
Adam B. Weiner, MD(+1 more)
1:27
The Expert APProach: Leveraging coding to demonstrate APP productivity and value
11 days ago
by
Joy Maulik, CRNP(+1 more)
0:47
Hans Arora, MD, PhD, discusses the role of APPs and nurses in surgical care
11 days ago
by
Hans Arora, MD, PhD
0:25
Early diagnosis and guideline-concordant penile cancer care
12 days ago
by
Luis G. Medina, MD
0:32
IVF-related incontinence: When to reassure vs refer
14 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
University of Florida urology chiefs Miranda Eubank, MD; Trisha Nguyen, MD; and Jordan Matthews-Smith, MD, reflect on residency milestones, mentorship, community, and lessons learned along the way.
This FAQ outlines what the State of Men's Health Act would do, how a federal Office of Men’s Health could affect research and clinical care, and what urologists can do to support the effort.
Emanuele Crupi, MD, discusses prospective data supporting GemFLP as a benchmark for treatment of advanced urachal and non-urachal urinary tract adenocarcinomas.
A TRUMPET registry analysis found that initial disease presentation and family history were associated with survival outcomes in metastatic castration-resistant prostate cancer.
Nicole L. Miller, MD, FACS, discusses how to distinguish bladder dysfunction from persistent obstruction when evaluating LUTS after BPH treatment.
Andrew J. Hung, MD, discusses an AI system that analyzes surgical gestures and identifies technique patterns linked to erectile function recovery after prostatectomy.
Datopotamab deruxtecan will be assessed alone and in combination with rilvegostomig as adjuvant treatment for patients with high-risk muscle-invasive urothelial carcinoma.
Host Amy Pearlman, MD, speaks with emergency physician Jeff Myers, DO, about his transition to sexual medicine and the importance of sexual health across specialties.
Davis Viprakasit, MD, FACS, discusses advanced cystoscopy training for APPs and the importance of collaboration between APPs and urologists to expand patient care.
A national cohort study found that metabolic syndrome and its components were frequently documented within the first year of concurrent ADT and ARPI therapy for prostate cancer.
Advertisement
Clinicians across four cities weigh ARASEC and ARANOTE trial data, drug interactions, and access barriers in mCSPC treatment decisions.
María Natalia Gandur Quiroga, MD, MSc, highlights treatment selection, negative trials, and implementation in GU oncology as 3 key themes emerging from ASCO 2026.
The phase 2 MODeFIRe-1 trial will evaluate investigational MRT-2359 plus apalutamide in AR-mutated metastatic castration-resistant prostate cancer.
Tyler Seibert, MD, PhD, discusses cribriform and intraductal carcinoma and their implications for risk stratification and treatment selection in prostate cancer.
Water vapor thermal therapy also provided greater QoL improvement vs combination pharmacotherapy while preserving sexual function.
Advertisement
Advertisement
Trending on Urology Times
1
Timothy McClure, MD, on 2-year PRESERVE trial results for focal IRE
2
Prof Declan Murphy discusses PROTEUS pathologic response findings in prostate cancer
3
FDA greenlights phase 1 trial of ADI-212 in mCRPC
4
Zachary Feuer, MD, on building a rapid access program for prostate cancer diagnostic evaluation
5